Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05524792Completed

Incidence of Diabetes After a COVID-19 Infection

Role: collaborator

NCT05365269Not ApplicableCompleted

Proactive Automatized Lifestyle Intervention

Role: collaborator

NCT02962908Phase 2Completed

A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine

Role: collaborator

NCT00833885Not ApplicableCompleted

Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal Influenza

Role: lead

All 4 trials loaded